Latest Conference Articles

Liso-Cel Induces High Rate of Durable Responses in LBCL

CD19-directed CAR T-cell therapy induced a high rate of rapid and durable complete responses in patients with aggressive relapsed/refractory large B-cell lymphoma.

Novel Triplet Shows Early Promise for Pretreated CLL

The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Triplet Regimen Induces High Rate of CR in R/R Follicular Lymphoma

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.

Dr. Tam on Results of the CAPTIVATE Trial in CLL

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Acalabrutinib Triplet Highly Active in Frontline CLL

The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL

With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.

Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL

The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.

Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.

Novel Antibody Elicits Complete Remissions in NHL After CAR Relapses

Mosunetuzumab, a novel bispecific antibody, generated durable responses in patients with highly refractory non-Hodgkin lymphomas, including complete remissions in 22.2% of those who had previously received chimeric antigen receptor T-cell therapy.

Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL

Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.

Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Fate Touts Novel Off-the-Shelf Cell Therapy

An investigational new drug application for the therapy, which is labeled FT596, was approved in September 2019 and human trials are scheduled to begin in the first quarter of 2020.

Landgren Previews Pivotal ASH 2019 Myeloma Data

Ahead of the 2019 ASH Annual Meeting, C. Ola Landgren, MD, PhD, shares insight on the potentially practice-changing data in the multiple myeloma paradigm that will be discussed at the conference.

Dr. Barocas on the CEASAR Trial in Localized Prostate Cancer

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Dr. Beckermann on Sequencing Strategies in mRCC

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Spartalizumab Plus Dabrafenib/Trametinib Impresses in BRAF+ Melanoma With Poor Prognosis

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

Dr. Shinohara on Stereotactic Body Radiotherapy to Treat Prostate Cancer

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.

CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ Melanoma

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.

Dr. Glitza on Intrathecal Nivolumab Approaches in Leptomeningeal Disease

Isabella C. Glitza, MD, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab for patients with metastatic melanoma and leptomeningeal disease.

Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

Neoadjuvant T-VEC May Improve Survival in Advanced Melanoma

Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.

Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma

Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.

Targeted Combos Improve OS in Melanoma, But Mitigating Toxicities Essential

Adil Daud, MD, discusses the role of dabrafenib plus trametinib in patients with advanced melanoma and highlighted other combinations under investigation.

Frontline Nivolumab/Ipilimumab Combo Delivers Long-Term OS Advantage in Melanoma

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a sustained survival benefit compared with nivolumab or ipilimumab alone, according to 5-year follow-up results.